Prevalence of vancomycin-resistant enterococci from three tertiary care hospitals and role of esp gene in biofilm formation
By: Mutiullah Khattak, Sabir Nawaz, Neak Muhammad, Asif Jamal, Sohail Akhtar, Rubina Kamran, Naeem Akhtar, Fariha Hasan, Aamer Ali Shah
Key Words: Enterococcus faecalis, Enterococcus faecium, Vancomycin resistance, Biofilm, esp gene
Int. J. Biosci. 10(3), 24-34, March 2017.Generate Certificate]
The purpose of this study was to elucidate antibiotic resistance profile of 143 Enterococcus spp. isolates against vancomycin and other antimicrobial agents from three Pakistani hospitals and to show a relationship between biofilm formation and esp gene as virulence factors. Different specimens, mainly, urine, blood and pus were processed for this purpose. Antibiotic resistance profile was elucidated through Kirby-Bauer disc diffusion and E-test methods. Isolates were screened for biofilm formation using microtiter plate method and the presence of esp gene was determined through Polymerase Chain Reaction (PCR). A Chi-square (χ^2) test was used to find association between biofilm formation and the presence of esp gene. Among 143 isolates, 25 (17.48%) were found to be Vancomycin-Resistant Enterococci (VRE). The resistance against linezolid was very low, i.e., only 01 isolate was resistant and 07 intermediately resistant. None of the isolates were found resistant to tigecycline. Among VRE, 90.5% Enterococcus faecium and 100% Enterococcus faecalis isolates were positive for biofilm formation. The association between biofilm formation and esp gene was found insignificant (p-value >0.05) for both vancomycin-resistant and sensitive isolates. The frequency of vancomycin resistance in Enterococcus spp. is gradually increasing in Pakistan. Beyond vancomycin, tigecycline, linezolid and teicoplanin were the most effective antimicrobial agents in a local hospital setting. Biofilm was formed in most of the isolates, which might cause nosocomial infections, regardless of the presence of esp gene.
Prevalence of vancomycin-resistant enterococci from three tertiary care hospitals and role of esp gene in biofilm formation
Abdulla FE, Abdulla EM. 2006. Antibiotic options for Enterococcus faecalis infection. Pakistan Journal of Medical Sciences 22, 286-290.
Anderson AC, Jonas D, Huber I, Karygianni L, Wölber J, Hellwig E, Arweiler N, Vach K, Wittmer A, Al-Ahmad A. 2016. Enterococcus faecalis from food, clinical specimens and oral sites: Prevalence of virulence factors in association of biofilm formation. Frontiers in Microbiology 6, 1534-1547.
Andrews J. 2013. BSAC methods for antimicrobial susceptibility testing(Version 12). British Society for Antimicrobial Chemotherapy, Birmingham, United Kingdom. In.
Babar N, Usman J, Munir T, Gill MM, Anjum R, Gilani M, Latif M. 2014. Frequency and antibiogram of vancomycin resistant enterococcus in a tertiary care hospital. Journal of the College of Physicians and Surgeons Pakistan 24, 27-29.
Betriu C, Rodríguez-Avial I, Sánchez BA, Gómez M, Álvarez J, Picazo JJ, Spanish Group of Tigecycline. 2002. In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain. Antimicrobial Agents and Chemotherapy 46, 892-895.
Bose S, Ghosh A, Barapatre R. 2012. Prevalence of drug resistance among Enterococcus species isolated from a tertiary care hospital. International Journal of Medical Health Sciences 1, 38-44.
Cercenado E, Cercenado S, Gómez JA, Bouza E. 2003. In vitro activity of tigecycline (GAR-936), a novel glycylcycline, against vancomycin-resistant enterococci and staphylococci with diminished susceptibility to glycopeptides. Journal of Antimicrobial Chemotherapy52, 138-139.
Chuang-Smith ON, Wells CL, Henry-Stanley MJ, Dunny GM. 2010. Acceleration of Enterococcus faecalis biofilm formation by aggregation substance expression in an ex vivo model of cardiac valve colonization. PLoS One 5, e15798.
Chuang ON, Schlievert PM, Wells CL, Manias DA, Tripp TJ, Dunny GM. 2009. Multiple functional domains of Enterococcus faecalis aggregation substance Asc10 contribute to endocarditis virulence. Infection and Immunity 77, 539-548.
CLSI. 2013. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Third Informational Supplement. CLSI document M100–S23. In.: Clinical and Laboratory Standards Institute Wayne, PA.
Da Silva NS, Muniz VD, Estofolete CF, Furtado GH, Rubio FG. 2014. Identification of temporal clusters and risk factors of bacteremia by nosocomial vancomycin-resistant enterococci. American Journal of Infection Control 42, 389-392.
De Kraker ME, Davey PG, Grundmann H, BURDEN Study Group. 2011. Mortality and hospital stay associated with resistant Staphylococcus aureus and Escherichia coli bacteremia: estimating the burden of antibiotic resistance in Europe. PLoS Medicine 8, e1001104.
Dworniczek E, Piwowarczyk J, Bania J, Kowalska-Krochmal B, Walecka E, Seniuk A, Dolna I, Gosciniak G. 2012. Enterococcus in wound infections: virulence and antimicrobial resistance. Acta Microbiologica et Immunologica Hungarica 59, 263-269.
Gaspar F, Teixeira N, Rigottier-Gois L, Marujo P, Nielsen-LeRoux C, Crespo MT, Lopes Mde F, Serror P. 2009. Virulence of Enterococcus faecalis dairy strains in an insect model: the role of fsrB and gelE. Microbiology 155, 3564-3571.
Gilmore MS, Lebreton F, Van Schaik W. 2013. Genomic transition of enterococci from gut commensals to leading causes of multidrug-resistant hospital infection in the antibiotic era. Current Opinion in Microbiology 16, 10-16.
Gozaydin A, Kose S, Ece G, Ersan G, Gonullu M. 2013. Detection of vancomycin resistant enterococci from rectal swab samples by Becton-Dickinson GeneOhm VanR assay and culture at ICU of a Tertiary Care Center in Turkey. Pakistan Journal of Medical Sciences 29, 682-686.
Hammerum A. 2012. Enterococci of animal origin and their significance for public health. Clinical Microbiology and Infection 18, 619-625.
Hayakawa K, Marchaim D, Vidaillac C, Lephart P, Pogue JM, Sunkara B, Kotra H, Hasan A, Shango M, Yerramalla Y, Osunlana AM, Chopra T, Dhar S, Salimnia H, Rybak MJ, Kaye KS. 2011. Growing prevalence of vancomycin-resistant Enterococcus faecalis in the region with the highest prevalence of vancomycin-resistant Staphylococcus aureus. Infection Control & Hospital Epidemiology 32, 922-924.
Jada S, Jayakumar K. 2012. Prevalence of Enterococcus species from various clinical specimens in Shri Sathya Sai Medical College and Research Institute with special reference to speciation and their resistance to vancomycin. International Journal of Medical and Clinical Research 3, 154-160.
Jones RN, Castanheira M, Hu B, Ni Y, Lin SS, Mendes RE, Wang Y. 2013. Update of contemporary antimicrobial resistance rates across China: reference testing results for 12 medical centers (2011). Diagnostic Microbiology and Infectious Disease 77, 258-266.
Kristich CJ, Li YH, Cvitkovitch DG, Dunny GM.2004.Esp-independentbiofilmformationby Enterococcusfaecalis.Journal of Bacteriology186, 154–163.
Lai CC, Chu CC, Cheng A, Huang YT, Hsueh PR. 2013. Correlation between antimicrobial consumption and incidence of health-care-associated infections due to methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci at a university hospital in Taiwan from 2000 to 2010. Journal of Microbiology,Immunology and Infection 48, 431-436.
Laishram S, Sahni RD, Anandan S, Balaji V.
- Evaluation of the antimicrobial activity of daptomycin and linezolid against vancomycin-resistant Enterococcus spp. isolates in south India. Journal of Global Antimicrobial Resistance 2, 194-197.
Lindenstrauss AG, Pavlovic M, Bringmann A, Behr J, Ehrmann MA, Vogel RF. 2011. Comparison of genotypic and phenotypic cluster analyses of virulence determinants and possible role of CRISPR elements towards their incidence in Enterococcus faecalis and Enterococcus faecium. Systematic and Applied Microbiology 34, 553-560.
Livermore DM. 2009. Has the era of untreatable infections arrived? Journal of Antimicrobial Chemotherapy 64, i29-i36.
Livermore DM.2012. Fourteen years in resistance. International Journal of Antimicrobial Agents 39, 283-294.
Majeed MT, Izhar M. 2006. In vitro activity of glycopeptides against clinical isolates of Entercocci from a tertiary care hospital. Annals of King Edward Medical University 12, 22-25.
Mohamed JA, Huang W, Nallapareddy SR, Teng F, Murray BE. 2004. Influence of origin of isolates, especially endocarditis isolates, and various genes on biofilm formation by Enterococcus faecalis. Infection and Immunity 72, 3658-3663.
Mohamed JA, Murray BE. 2004. Lack of correlation of gelatinase production and biofilm formation in a large collection of Enterococcus faecalis isolates. Journal of Clinical Microbiology 43, 5405-5407.
Molton JS, Tambyah PA, Ang BS, Ling ML, Fisher DA. 2013. The global spread of healthcare-associated multidrug-resistant bacteria: a perspective from Asia. Clinical Infectious Diseases 56, 1310-1318.
Mulder R, Farnham S, Grinius B. 1995. Evaluating antimicrobial susceptibility test systems. Washington DC: ASM Press.
Murdoch DR, Mirrett S, Harrell LJ, Monahan JS, Reller LB. 2002. Sequential emergence of antibiotic resistance in enterococcal bloodstream isolates over 25 years. Antimicrobial Agents and Chemotherapy 46, 3676-3678.
Nateghian A, Ahari SMG, Harahdashti AL, Navidnia M, Mehrazma M. 2014. Prevalence of vancomycin-resistant Enterococci colonization, and susceptibility to linezolid in Pediatric Intensive Care Units of a Referral Pediatric Center in Tehran, Iran. Archives of Pediatric Infectious Diseases 2, e16970. http://dx.doi.org/10.5812/pedinfect.16970.
Olson MW, Ruzin A, Feyfant E, Rush TS III, O’Connell J, Bradford PA. 2006. Functional, biophysical, and structural bases for antibacterial activity of tigecycline. Antimicrobial Agents and Chemotherapy 50, 2156-2166.
Pankey GA. 2005. Tigecycline. Journal of Antimicrobial Chemotherapy 56, 470-480.
Rubinstein E, Keynan Y. 2013. Vancomycin-resistant enterococci. Critical Care Clinics 29, 841-852.
Shankar N, Lockatell CV, Baghdayan AS, Drachenberg C, Gilmore MS, Johnson DE. 2001. Role of Enterococcus faecalissurface protein ESP in the pathogenesis of ascending urinary tract infection. Infection and Immunity 69, 4366-4372. http://dx.doi.org/10.1128/IAI.69.7.4366-4372.2001.
Shankar V, Baghdayan AS, Huycke MM, Lindahl G, Gilmore MS. 1999. Infection-derived Enterococcus faecalis strains are enriched in esp, a gene encoding a novel surface protein. Infection and Immunity 67, 193-200.
Shokoohizadeh L, Mobarez AM, Zali MR, Ranjbar R, Alebouyeh M, Sakinc T, Ali L. 2013. High frequency distribution of heterogeneous vancomycin resistant Enterococcous faecium (VREfm) in Iranian hospitals. Diagnostic Pathology 8, 163-167.
Sievert DM, Ricks P, Edwards JR, Schneider A, Patel J, Srinivasan A, Kallen A, Limbago B, Fridkin S, National Healthcare Safety Network (NHSN) Team, Participating NHSN Facilities. 2013. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009–2010. Infection Control and Hospital Epidemiology 34, 1-14.
Sillanpää J, Nallapareddy SR, Singh KV, Prakash VP, Fothergill T, Ton-That H, Murray BE. 2010. Characterization of the ebp(fm) pilus-encoding operon of Enterococcus faecium and its role in biofilm formation and virulence in a murine model of urinary tract infection. Virulence 1, 236-246.
Stein GE, Craig WA. 2006. Tigecycline: a critical analysis. Clinical Infectious Diseases 43, 518-524. http://dx.doi.org/10.1086/505494.
Theuretzbacher U. 2013. Global antibacterial resistance: The never-ending story. Journal of Global Antimicrobial Resistance 1, 63-69.
Treitman AN, Yarnold PR, Warren J, Noskin GA. 2005. Emerging incidence of Enterococcus faecium among hospital isolates (1993 to 2002). Journal of Clinical Microbiology 43, 462-463.
Upadhyaya GP, Lingadevaru UB, Lingegowda RK. 2010. Comparative study among clinical and commensal isolates of Enterococcus faecalis for presence of esp gene and biofilm production. The Journal of Infection in Developing Countries 5, 365-369.
Upadhyaya PG, Ravikumar K, Umapathy B. 2009. Review of virulence factors of enterococcus: an emerging nosocomial pathogen. Indian Journal of Medical Microbiology 27, 301-305.
Waites KB, Duffy LB, Dowzicky MJ. 2006. Antimicrobial susceptibility among pathogens collected from hospitalized patients in the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial. Antimicrobial Agents and Chemotherapy 50, 3479-3484.
Wang JT, Chang SC, Wang HY, Chen PC, Shiau YR, Lauderdale TL, TSAR Hospitals. 2013. High rates of multidrug resistance in Enterococcus faecalis and E. faecium isolated from inpatients and outpatients in Taiwan. Diagnostic Microbiology and Infectious Disease 75, 406-411. http://dx.doi.org/10.1016/j.diagmicrobio.2013.01.004.
Yameen MA, Iram S, Mannan A, Khan SA, Akhtar N. 2013. Nasal and perirectal colonization of vancomycin sensitive and resistant enterococci in patients of paediatrics ICU (PICU) of tertiary health care facilities. BMC Infectious Diseases 13, 156-165. http://dx.doi.org/10.1186/1471-2334-13-156.
Zhanel GG, Harding GK, Rosser S, Hoban DJ,
Karlowsky JA, Alfa M, Kabani A, Embil J, Gin A, Williams T, Nicolle LE. 2000. Low prevalence of VRE gastrointestinal colonization of hospitalized patients in Manitoba tertiary care and community hospitals. Canadian Journal of Infectious Diseases and Medical Microbiology 11, 38-41.
Prevalence of vancomycin-resistant enterococci from three tertiary care hospitals and role of esp gene in biofilm formation.
Int. J. Biosci. 10(3), 24-34, March 2017.
By Authors and International Network for
Natural Sciences (INNSPUB)